sodium-β-O-methyl cellobioside sulfate

sodium-β-O-methyl cellobioside sulfate (also known as STC3141 or mCBS.Na) is a small, carbohydrate-based polyanionic compound designed to act as an extracellular histone neutralizer. Developed through a collaboration between Griffith University and the Australian National University, and licensed to Grand Pharmaceutical Group, the drug works by electrostatically interacting with and neutralizing positively charged extracellular histones and neutrophil extracellular traps (NETs). Extracellular histones are major damage-associated molecular patterns (DAMPs) that drive systemic inflammation, endothelial injury, and organ dysfunction in severe conditions. By neutralizing these histones, the drug aims to reverse organ damage and restore immune homeostasis without causing the significant anticoagulant effects associated with heparin. It is primarily being developed for the treatment of sepsis, acute respiratory distress syndrome (ARDS), and severe COVID-19 pneumonia.

Other names

beta-O-methyl cellobioside sulfatebeta-methyl-cellobioside sulfatemCBSmCBS.Namethyl cellobiose sulfatemethyl cellobiose sulfate sodium saltsodium-beta-O-methyl cellobioside sulfateβ-O-methyl cellobioside sulfate